Phase 2 Randomized, Double Blinded, Controlled Study of Tucatinib vs. Placebo in Combination with Capecitabine and Trastuzumab in Patients with Pretreated Unresectable Locally Advanced or Metastatic Her2+ Breast Carcinoma (HER2CLIMB)

Active:	Yes
Cancer Type:	Breast Cancer	NCT ID:
Trial Phases:	Phase II	Protocol IDs:	ONT-380-206 (primary)
Eligibility:	, Male and Female	Study Type:	Treatment
Study Sponsor:	Cascadian Theraputics, Inc
NCI Full Details:

Objectives

Primary To assess the effect of Tucatinib vs. placebo in combination with capecitabine and trastuzumab on progression-free survival per RECIST 1.1 based on independent central review

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.